

David M Gershenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2256514/publications.pdf>

Version: 2024-02-01

122
papers

8,567
citations

31902

53
h-index

46693

89
g-index

123
all docs

123
docs citations

123
times ranked

5562
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7. | | 2 |
| 2 | Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 541-553. | 6.3 | 75 |
| 3 | Ovarian mucinous neoplasms, intestinal type, in premenopausal patients, develop in abnormal ovaries. Human Pathology, 2021, 108, 32-41. | 1.1 | 2 |
| 4 | MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treatment Reviews, 2021, 92, 102137. | 3.4 | 85 |
| 5 | Fertility preservation in rare ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 432-441. | 1.2 | 4 |
| 6 | Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecologic Oncology, 2021, 162, 728-734. | 0.6 | 4 |
| 7 | Sex cord-stromal tumors of the ovary: road map for progress. International Journal of Gynecological Cancer, 2021, 31, 169-170. | 1.2 | 2 |
| 8 | Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. International Journal of Gynecological Cancer, 2020, 30, 1768-1774. | 1.2 | 2 |
| 9 | The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy. Cancers, 2020, 12, 3043. | 1.7 | 9 |
| 10 | Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors. Gynecologic Oncology, 2020, 159, 601-603. | 0.6 | 3 |
| 11 | The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecologic Oncology, 2020, 158, 653-658. | 0.6 | 29 |
| 12 | Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1733-1737. | 1.2 | 4 |
| 13 | MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype. Journal of Clinical Oncology, 2020, 38, 3731-3734. | 0.8 | 10 |
| 14 | Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations. Scientific Reports, 2020, 10, 20678. | 1.6 | 6 |
| 15 | Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum. Gynecologic Oncology Reports, 2020, 34, 100670. | 0.3 | 1 |
| 16 | Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature. Gynecologic Oncology Reports, 2020, 32, 100576. | 0.3 | 2 |
| 17 | Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord- Stromal Tumors: A Contemporary Review. Cancers, 2020, 12, 1398. | 1.7 | 24 |
| 18 | Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology, 2020, 157, 3-11. | 0.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. <i>Gynecologic Oncology</i> , 2020, 157, 21-28. | 0.6 | 8 |
| 20 | Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020, 156, 715-725. | 0.6 | 74 |
| 21 | Rare Gynecologic Tumors: Coming of Age. <i>Gynecologic Oncology</i> , 2020, 157, 1-2. | 0.6 | 2 |
| 22 | Significance of lymph node ratio on survival of women with borderline ovarian tumors. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1289-1298. | 0.8 | 8 |
| 23 | Management of Rare Ovarian Cancer Histologies. <i>Journal of Clinical Oncology</i> , 2019, 37, 2406-2415. | 0.8 | 19 |
| 24 | Low grade serous ovarian carcinoma: identifying variations in practice patterns. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 174-180. | 1.2 | 9 |
| 25 | Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972. | 2.0 | 39 |
| 26 | Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. <i>Gynecologic Oncology</i> , 2019, 153, 230-237. | 0.6 | 16 |
| 27 | Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 87-93. | 0.3 | 18 |
| 28 | Clinical trial methodology in rare gynecologic tumor research: Strategies for success. <i>Gynecologic Oncology</i> , 2018, 149, 605-611. | 0.6 | 8 |
| 29 | Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 236-244. | 0.8 | 8 |
| 30 | Treatment of Rare Epithelial Ovarian Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1011-1024. | 0.9 | 16 |
| 31 | Trends of low-grade serous ovarian carcinoma in the United States. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e15. | 1.0 | 29 |
| 32 | Complete Resection Is Essential in the Surgical Treatment of Gestational Trophoblastic Neoplasia. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1453-1460. | 1.2 | 1 |
| 33 | Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). <i>Gynecologic Oncology</i> , 2018, 150, 9-13. | 0.6 | 44 |
| 34 | KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. <i>Nature Communications</i> , 2018, 9, 2496. | 5.8 | 39 |
| 35 | Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. <i>Gynecologic Oncology</i> , 2017, 145, 37-40. | 0.6 | 51 |
| 36 | Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2017, 144, 496-502. | 0.6 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | On-Site Fertility Preservation Services for Adolescents and Young Adults in a Comprehensive Cancer Center. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 229-234. | 0.7 | 9 |
| 38 | DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. <i>Gynecologic Oncology</i> , 2017, 147, 521-527. | 0.6 | 87 |
| 39 | FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 147, 3-10. | 0.6 | 36 |
| 40 | An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249. | 0.6 | 61 |
| 41 | Contemporary Treatment Strategies for Rare Epithelial Ovarian Cancers. <i>Current Obstetrics and Gynecology Reports</i> , 2017, 6, 228-236. | 0.3 | 0 |
| 42 | Management of borderline ovarian tumours. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 49-59. | 1.4 | 73 |
| 43 | ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 16951-16963. | 0.8 | 82 |
| 44 | Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. <i>Cancer</i> , 2016, 122, 230-237. | 2.0 | 91 |
| 45 | Ovarian Sex Cord-Stromal Tumors. <i>Journal of Oncology Practice</i> , 2016, 12, 940-946. | 2.5 | 71 |
| 46 | Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment. <i>Gynecologic Oncology</i> , 2016, 143, 428-432. | 0.6 | 30 |
| 47 | Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. <i>Abdominal Radiology</i> , 2016, 41, 1589-1595. | 1.0 | 13 |
| 48 | Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. <i>Oncotarget</i> , 2016, 7, 56933-56943. | 0.8 | 34 |
| 49 | The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. <i>Gynecologic Oncology</i> , 2015, 136, 25-29. | 0.6 | 51 |
| 50 | Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. <i>Journal of Clinical Oncology</i> , 2015, 33, 2675-2682. | 0.8 | 91 |
| 51 | Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series. <i>Gynecologic Oncology Reports</i> , 2015, 13, 36-39. | 0.3 | 6 |
| 52 | Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 930-936. | 0.8 | 247 |
| 53 | Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. <i>British Journal of Cancer</i> , 2015, 113, 1254-1258. | 2.9 | 63 |
| 54 | Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all. <i>Gynecologic Oncology</i> , 2015, 136, 373-383. | 0.6 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS ONE, 2015, 10, e0135101. | 1.1 | 38 |
| 56 | Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group. Cancer, 2014, 120, 344-351. | 2.0 | 71 |
| 57 | Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecologic Oncology, 2014, 133, 100-104. | 0.6 | 22 |
| 58 | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncology, The, 2013, 14, 134-140. | 5.1 | 322 |
| 59 | Survival in Women With Grade 1 Serous Ovarian Carcinoma. Obstetrics and Gynecology, 2013, 122, 225-232. | 1.2 | 78 |
| 60 | The Life and Times of Low-Grade Serous Carcinoma of the Ovary. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e195-e199. | 1.8 | 16 |
| 61 | The Life and Times of Low-Grade Serous Carcinoma of the Ovary. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e195-e199. | 1.8 | 7 |
| 62 | Treatment of Ovarian Cancer in Young Women. Clinical Obstetrics and Gynecology, 2012, 55, 65-74. | 0.6 | 47 |
| 63 | Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology, 2012, 125, 661-666. | 0.6 | 166 |
| 64 | Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. Gynecologic Oncology, 2012, 125, 515-517. | 0.6 | 57 |
| 65 | Low-grade serous primary peritoneal carcinoma. Gynecologic Oncology, 2011, 121, 482-486. | 0.6 | 42 |
| 66 | Prevalence of Lymph Node Metastasis in Primary Mucinous Carcinoma of the Ovary. Obstetrics and Gynecology, 2010, 116, 269-273. | 1.2 | 76 |
| 67 | A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer, 2010, 116, 5415-5419. | 2.0 | 222 |
| 68 | Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 4142-4149. | 0.8 | 37 |
| 69 | Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?. Gynecologic Oncology, 2009, 113, 86-90. | 0.6 | 153 |
| 70 | Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecologic Oncology, 2009, 114, 48-52. | 0.6 | 234 |
| 71 | Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecologic Oncology, 2009, 114, 431-436. | 0.6 | 82 |
| 72 | Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation. Gynecologic Oncology, 2009, 115, 6-11. | 0.6 | 111 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , 2008, 108, 510-514. | 0.6 | 203 |
| 74 | Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2792-2797. | 0.8 | 172 |
| 75 | Management of Ovarian Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2938-2943. | 0.8 | 268 |
| 76 | Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2007, 105, 404-408. | 0.6 | 126 |
| 77 | Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 625-629. | 0.6 | 69 |
| 78 | Quality of life in long-term survivors of ovarian germ cell tumors: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2007, 105, 687-694. | 0.6 | 41 |
| 79 | The Recurrence and the Overall Survival Rates of Ovarian Serous Borderline Neoplasms With Noninvasive Implants is Time Dependent. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1367-1371. | 2.1 | 162 |
| 80 | Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2006, 108, 361-368. | 1.2 | 242 |
| 81 | Fertility-Sparing Surgery for Malignancies in Women. <i>Journal of the National Cancer Institute Monographs</i> , 2005, 2005, 43-47. | 0.9 | 89 |
| 82 | The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 3517-3523. | 0.8 | 82 |
| 83 | Grading Ovarian Serous Carcinoma Using a Two-Tier System. <i>American Journal of Surgical Pathology</i> , 2004, 28, 496-504. | 2.1 | 592 |
| 84 | Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. <i>Modern Pathology</i> , 2004, 17, 75-80. | 2.9 | 5 |
| 85 | Calcifications in Ovary and Endometrium and Their Neoplasms. <i>Modern Pathology</i> , 2003, 16, 219-222. | 2.9 | 28 |
| 86 | Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. <i>Obstetrics and Gynecology</i> , 2002, 99, 3-10. | 1.2 | 204 |
| 87 | Clinical management potential tumours of low malignancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 513-527. | 1.4 | 71 |
| 88 | Irinotecan in epithelial ovarian cancer. <i>Oncology</i> , 2002, 16, 29-31. | 0.4 | 6 |
| 89 | Fluorescence spectroscopy for in vivo characterization of ovarian tissue. <i>Lasers in Surgery and Medicine</i> , 2001, 29, 128-135. | 1.1 | 44 |
| 90 | Reflectance spectroscopy for in vivo characterization of ovarian tissue. <i>Lasers in Surgery and Medicine</i> , 2001, 28, 56-66. | 1.1 | 88 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. <i>Molecular and Cellular Biochemistry</i> , 2001, 217, 21-33. | 1.4 | 35 |
| 92 | Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer. <i>Annals of Internal Medicine</i> , 2000, 132, 364. | 2.0 | 149 |
| 93 | Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 459-468. | 2.0 | 25 |
| 94 | Outcome and reproductive function after conservative surgery for borderline ovarian tumors. <i>Obstetrics and Gynecology</i> , 2000, 95, 541-547. | 1.2 | 146 |
| 95 | Pharmacoeconomic Considerations in Treating Ovarian Cancer. <i>Pharmacoeconomics</i> , 2000, 17, 133-150. | 1.7 | 13 |
| 96 | Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 2676-2676. | 0.8 | 199 |
| 97 | Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2670-2670. | 0.8 | 168 |
| 98 | HER-2/ neu peptide specificity in the recognition of HLA-A2 by natural killer cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 401-410. | 2.0 | 0 |
| 99 | The current status of surgical staging of ovarian serous borderline tumors. , 1999, 85, 905-911. | | 120 |
| 100 | A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. <i>Cancer</i> , 1999, 86, 2291-2300. | 2.0 | 4 |
| 101 | Contemporary Treatment of Borderline Ovarian Tumors. <i>Cancer Investigation</i> , 1999, 17, 206-210. | 0.6 | 45 |
| 102 | Ovarian serous borderline tumors with invasive peritoneal implants. <i>Cancer</i> , 1998, 82, 1096-1103. | 2.0 | 186 |
| 103 | Serous borderline tumors of the ovary with noninvasive peritoneal implants. <i>Cancer</i> , 1998, 83, 2157-2163. | 2.0 | 162 |
| 104 | Ovarian serous borderline tumors with invasive peritoneal implants. <i>Cancer</i> , 1998, 82, 1096-1103. | 2.0 | 5 |
| 105 | Sexual adjustment of patients undergoing Gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. <i>Cancer</i> , 1996, 78, 2229-2235. | 2.0 | 73 |
| 106 | Infusion site soft-tissue injury after paclitaxel administration. <i>Cancer</i> , 1995, 76, 116-120. | 2.0 | 33 |
| 107 | Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors. <i>Journal of Surgical Oncology</i> , 1994, 10, 290-298. | 1.4 | 13 |
| 108 | Salvage Surgery for Chemorefractory Ovarian Germ Cell Tumors. <i>Gynecologic Oncology</i> , 1994, 55, 217-223. | 0.6 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Ovarian Carcinomas with Transitional Cell Carcinoma Patter. American Journal of Clinical Pathology, 1990, 93, 457-465. | 0.4 | 101 |
| 110 | Sexual dysfunction and treatment for early stage cervical cancer. Cancer, 1989, 63, 204-212. | 2.0 | 203 |
| 111 | Nature of cervical involvement in endometrial carcinoma. Cancer, 1987, 59, 959-962. | 2.0 | 19 |
| 112 | Prognostic factors in stage II endometrial carcinoma. Cancer, 1987, 60, 1358-1361. | 2.0 | 29 |
| 113 | Second-Look Laparotomy in the Management of Malignant Germ Cell Tumors of the Ovary. Obstetrics and Gynecology, 1986, 67, 789-793. | 1.2 | 49 |
| 114 | Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin. Cancer, 1986, 57, 1731-1737. | 2.0 | 54 |
| 115 | Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer, 1986, 58, 1407-1410. | 2.0 | 30 |
| 116 | Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma: Potential for cure and preservation of reproductive capacity. Cancer, 1986, 58, 2594-2599. | 2.0 | 40 |
| 117 | Microscopic disease at second-look laparotomy in advanced ovarian cancer. Cancer, 1985, 55, 472-478. | 2.0 | 107 |
| 118 | Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer, 1985, 55, 1129-1135. | 2.0 | 120 |
| 119 | Mucinous tumors of the ovary. A clinicopathologic study of 70 cases. Cancer, 1985, 55, 1958-1962. | 2.0 | 59 |
| 120 | Endodermal sinus tumor of the vagina and cervix. Cancer, 1985, 55, 2558-2565. | 2.0 | 104 |
| 121 | Alveolar rhabdomyosarcoma of the female genitalia. Cancer, 1985, 56, 849-855. | 2.0 | 49 |
| 122 | Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer, 1985, 56, 2756-2761. | 2.0 | 84 |